A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis (NCT04772079)
A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Deucravacitinib (BMS-986165) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort. Part A will evaluate the drug levels of BMS-986165 to enable selection of 2 dose levels to be studied in Part B. Part B will assess the efficacy and safety of two dose levels in children and adolescent participants with moderate to severe plaque psoriasis. The 5-year long-term extension (LTE) period will observe the long-term safety and tolerability of deucravacitinib in children and adolescent participants with psoriasis who have completed Parts A or B of the study.
Who can join: Review the eligibility criteria below.
Location: Instituto de Neumonologia Y Dermatologia — Ciudad Autonoma de Buenos Aires, Buenos Aires
Age range: 4 Years to 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (65 Sites)
Showing the first 25 of 65 sites.
- Instituto de Neumonologia Y Dermatologia — Ciudad Autonoma de Buenos Aires, Buenos Aires
- Psoriahue — Ciudad Autonoma de Buenos Aires, Buenos Aires
- CONEXA Investigacion Clinica S.A. — Buenos Aires,
- Centro de Investigaciones Metabólicas (CINME) — Buenos Aires,
- Hospital Italiano de Buenos Aires — CABA,
- Consultora Integral de Salud — Córdoba,
- Local Institution - 0020 — Darlinghurst, New South Wales
- Local Institution - 0002 — Westmead, New South Wales
- Queensland Children's Hospital — Brisbane, Queensland
- Local Institution - 0003 — Woolloongabba, Queensland
- Monash Health — Clayton, Victoria
- Local Institution - 0001 — Melbourne, Victoria
- Centro de Pesquisas da Clínica IBIS — Salvador, Estado de Bahia
- Hospital Moinhos de Vento — Porto Alegre, Rio Grande do Sul
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (USP) - HCFMRP — Ribeirão Preto, São Paulo
- Local Institution - 0083 — Rio de Janeiro,
- Local Institution - 0067 — São Paulo,
- Local Institution - 0010 — Calgary, Alberta
- Alberta Dermasurgery Centre — Edmonton, Alberta
- Local Institution - 0039 — Hamilton, Ontario
- Lynderm Research Inc. — Markham, Ontario
- The Hospital for Sick Children — Toronto, Ontario
- Centre Hospitalier de Calais — Calais,
- Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand-dermatology — Dijon,
- Centre Hospitalier Universitaire de Nice - Hôpital l'Archet — Nice,
📞 Contact the Study Coordinator
Phone: (855) 907-3286
Email: Clinical.Trials@bms.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Plaque Psoriasis
- A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis — Phoenix, Arizona
- Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis — Phoenix, Arizona
- A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis — Birmingham, Alabama
- Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects — Rogers, Arkansas
- Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis — Birmingham, Alabama
- A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) — Phoenix, Arizona
Explore by condition: All Plaque Psoriasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.